Topical r-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis

Skin Pharmacology and Physiology

Volumn 9, Issue 5, 1996, Pages 307-311

  van de Kerkhof, P C M ^a   van Pelt, H ^a   Lucker, G P H ^a   Steijlen, P M ^a   Heremans, A ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

5 Lipoxygenase; Epidermis; Inflammation; Psoriasis

Indexed keywords

ANTIPSORIASIS AGENT; ARACHIDONATE 5 LIPOXYGENASE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; R 68151; R 85355; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BURN; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; HUMAN; INFLAMMATION; KERATINIZATION; MALE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOXYGENASE INHIBITORS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PSORIASIS; TRIAZOLES;

EID: 0029730898     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000211431     Document Type: Article

References (13)

1. van de Kerkhof PCM, Bos JD: Pathogenetic aspects of psoriasis, Clin Dermatol 1995;13:97-161.
2. Greaves MW, Camp RDR: Prostaglandins, leukotrienes, phospholi-pasc Ai, platelet activating factors and cytokines: An integrated approach to inflammation of human skin, Arch Dermatol Res 1988:280: S33-S41.
3. Ziboh VA, Tamara L, Casebolt BS, Marcelo CL, Voorhccs JJ: Biosynthesis of lipoxygenase products by enzyme preparations from normal and psoriatic skin, J Invest Dermatol 1984;83:426-430.
4. van de Kerkhof PCM, Chang A: Transdermal and epidermal migration of polymorphonuclear leukocytes, Skin Pharmacol 1989:2:138- 154.
5. Allen BR, Littlewood SM: Benoxa-profen: Effect on cutaneous lesions in psoriasis, Br Med J 1982;285: 1241.
6. Kragballe K, Herlin T: Benoxaprof-cn improves psoriasis, Arch Dermatol 1983;119:548-552.
7. de Jong EMGJ, Schölte JCM, Buntinx A, Friedman B, Tanaka W, van dc Kerkhof PCM: Clinical and biochemical effects of an oral leuko-tricne biosynthesis inhibitor (MK886) in psoriasis, Skin Pharmacol 1991:4:278-285.
8. Kobza Black A, Camp RDR, Mallet AI, Cunningham FM, Hofbaucr M, Greaves MW: Pharmacologic and clinical effects of lonapalenc (RS 43179), a 5 lipoxygenase inhibitor, in psoriasis, J Invest Dermatol 1990;95:50-54.
9. Lassus A, Forsstrom S: A dimc-thoxynaphthalenc derivative (RS-43179 gel) compared with 0.025% fluocinolonc acetonide gel in the treatment of psoriasis, Br J Dermatol 1985;113:103-106.
10. Dcgreef H, Dockx P, de Doncker P, De Beule K, Cauwenbergh G: A double-blind vehicle controlled study of R 58121 in psoriasis: A topical 5-lipoxygcnase inhibitor, J Am Acad Dermatol 1990;22:754-755.
11. Beetens JR, Somers Y, Goossens J, van Wouwe J, de Clerck F: R 68151 inhibits the metabolism of arachi-donic acid via the 5-lipoxygenasc, Arch Int Pharmacodyn 1978:290: 151-160.
12. Beetens JR, Becrens D, van Ammel K, Somers Y, Loots W, dc Clerck F: R 85355: A potent, orally active 5-lipoxygenasc inhibitor, Pflügers Arch 1991;419:R1 -R14.
13. Beetens JR, Becrens D, Cools W, Caene MC, van Ammel K, van dc Wiele R, de Clerck F: Data on file, Janssen Research Foundation